Details of Disease

General Information of Disease (ID: DIS7OJYM)

• Disease Name: Respiratory tract infection
• Synonyms: infections, respiratory; infections, respiratory tract; infection, respiratory tract; infections, upper respiratory tract; respiratory infections; infections, upper respiratory; respiratory tract infection; upper respiratory infections; upper respiratory tract infections; respiratory infection, upper
• Disease Class: CA07-CA4Z: Respiratory infection
• Definition: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.
• Disease Hierarchy:
  DISGGAGJ: Respiratory disease
  DISEM33Q: Infectious disease
  DIS7OJYM: Respiratory tract infection
• ICD Code:
  ICD-11: ICD-11: CA45
  ICD-10: ICD-10: J13, J15
• Disease Identifiers:
  MONDO ID: MONDO_0024355
  MESH ID: D012141
  MedGen ID: 11199
  HPO ID: HP:0011947
  SNOMED CT ID: 275498002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 10 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cefaclor	DMJXDGC	Approved	Small molecular drug	[1]
Cefixime	DMY60I8	Approved	Small molecular drug	[2]
Cefotiam	DMF5HU6	Approved	Small molecular drug	[3]
Cefprozil	DM7DSYP	Approved	Small molecular drug	[4]
Cefradine	DMUNSWV	Approved	Small molecular drug	[5]
Colistimethate	DMZ9BMU	Approved	Small molecular drug	[6]
Gatifloxacin	DMSL679	Approved	Small molecular drug	[7]
Penicillin V	DMKVOYF	Approved	Small molecular drug	[8]
Tebipenem pivoxil	DMQ5S6C	Approved	Small molecular drug	[9]
Ceftolozane sulfate	DMYGEH7	Phase 4	Small molecular drug	[10]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Benzylpenicillin	DMS9503	Phase 3	Small molecular drug	[11]
RBT-101	DMDZW8K	Phase 3	NA	[12]
RTB101	DM62QTW	Phase 3	Small molecular drug	[13]
Pravibismane	DMSG0FP	Phase 2	Small molecular drug	[14]
BC-3205	DMGFABM	Phase 1	Small molecular drug	[15]
PF-4287881	DM7ZC7C	Phase 1	NA	[16]
TP-271	DM3PJSE	Phase 1	Small molecular drug	[17]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABI-0043	DMA7LUK	Preclinical	Small molecular drug	[18]
Cytoporins	DM9PJ8P	Preclinical	NA	[19]

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DW-286	DMIJ88X	Investigative	Small molecular drug	[20]
NB-401	DMLCA68	Investigative	NA	[20]
NM-001	DM2JH5B	Investigative	NA	[20]
NP-432	DMA38GY	Investigative	NA	[20]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Cefaclor FDA Label
• [2] Cefixime FDA Label
• [3] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [4] Cefprozil FDA Label
• [5] Cefazolin. Ann Intern Med. 1978 Nov;89(5 Pt 1):650-6.
• [6] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064216.
• [7] Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
• [8] Penicillin V FDA Label
• [9] Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00603-19.
• [10] ClinicalTrials.gov (NCT02421120) Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients. U.S. National Institutes of Health.
• [11] Benzylpenicillin versus wide-spectrum beta-lactam antibiotics as empirical treatment of Haemophilus influenzae-associated lower respiratory tract infections in adults; a retrospective propensity score-matched study. Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1761-1775.
• [12] Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
• [13] ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT02436876) Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites. U.S. National Institutes of Health.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029896)
• [16] ClinicalTrials.gov (NCT00793000) Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT03234738) A Phase 1 Safety and PK Study of IV TP-271. U.S. National Institutes of Health.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021301)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021100)
• [20] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.